The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain.
Victor Moreno
No relevant relationships to disclose
Brezo Martinez-Amores
Consultant or Advisory Role - Merck Serono (U)
Jorge Barriuso
No relevant relationships to disclose
Laura Mezquita
No relevant relationships to disclose
Inmaculada Ibañez de Cáceres
No relevant relationships to disclose
Angel Ayuso Sacido
No relevant relationships to disclose
Jose Maria Peña
No relevant relationships to disclose
Rosario Perona
No relevant relationships to disclose
Cristobal Belda-Iniesta
No relevant relationships to disclose